top of page
Search

Patient Retention: Keeping Participants Enrolled Once They're Recruited

Writer: Guy hudson
Guy hudson
Nov 12
8 min read

Clinical trial participant retention is the work of supporting people to remain involved long enough to complete the study activities they agreed to, including follow-up assessments. It matters because missing outcome data can make results less precise or harder to interpret. Retention is not the same as persuading everyone to stay: participants remain free to stop treatment, change what they do, or withdraw in line with the study information and applicable requirements. Strong retention begins with a trial that fits people's lives, explains what participation involves and responds promptly when the experience becomes difficult.

What Clinical Trial Participant Retention Means

Retention describes whether participants remain involved and provide required follow-up information. Define it against the protocol and study outcomes, not as one universal percentage. Someone may stop treatment but continue assessments, miss one visit and return, or withdraw from further contact. Record these as distinct events.

Withdrawal, Missed Visits And Loss To Follow-Up

A missed appointment is an incomplete visit, not automatically a withdrawal. Loss to follow-up generally means the team cannot re-establish contact or obtain the planned outcome data after appropriate attempts. Withdrawal is a participant's decision to stop some or all study involvement. The exact scope can vary: someone may stop study treatment but agree to safety checks, or decline further contact entirely. The protocol, consent materials and approved procedures should explain these options clearly.

This distinction matters operationally: a participant unable to travel may still complete a suitable remote assessment, while someone stopping treatment may choose to continue safety or outcome visits. Explain options without pressure, document the decision and follow the protocol. Do not equate retention with treatment adherence.

Why Retention Matters To Trial Quality

When people do not complete planned assessments, the missing information can reduce precision and may bias results if missingness relates to health status, treatment experience or another factor linked to outcomes. The direction and size of any bias depend on why data are missing and how the analysis handles it; a headline dropout rate alone cannot tell a reader whether results are reliable. Trial teams need to understand who is missing, which data are absent and at what point.

A 2026 qualitative evidence synthesis in BMJ Open identified fluctuating health, competing trial and life demands, the burden of data collection, and expectations that did not match the experience as influences on non-completion. The authors also note that participants may stop returning questionnaires without formally leaving the study. The findings point to a useful design question: is the burden necessary for the research question, and is the reason for each follow-up activity clear to the person completing it? Read the BMJ Open synthesis.

Missed assessments create site follow-up work and can complicate timelines and analysis. Every participant lost after enrolment also has to be replaced, which pushes the team back to the start of the recruitment funnel. The goal is meaningful data collection while respecting choice, safety and wellbeing, not attendance at any cost.

Why Participants Drop Out Or Stop Completing Follow-Up

Reasons change over time: someone motivated at enrolment may later face a different balance of effort, health and daily pressures.

Health Changes And Competing Demands

A condition can improve, worsen or become more difficult to manage. Fatigue, pain, treatment effects, a new diagnosis or other health needs may leave less capacity for a study visit or questionnaire. Work, caring responsibilities, travel, cost, school schedules or unstable internet access can also make repeated tasks difficult. These barriers may signal that the schedule or follow-up method does not fit the participant's circumstances.

Expectations That Do Not Match The Study

People may remember the possible personal benefit more strongly than the time commitment, randomisation, uncertainty of treatment allocation or repeated data collection. If the actual visit schedule differs from what they understood at consent, trust can erode. Complex information or unclear explanations of why follow-up matters can make an assessment feel pointless, especially after treatment has stopped.

Friction In Communication And Study Processes

Unanswered questions, repeated requests for the same information, confusing appointment instructions, staff changes or reminders that arrive at the wrong time can weaken engagement. Digital tools may exclude some people; a remote questionnaire is not automatically easier than a phone call or paper form.

Plan Retention Before The First Participant Enrols

Retention is not a rescue activity to add only after completion rates fall. A qualitative study of 24 UK and Irish trialists found that teams often plan strategies during protocol development, then add measures when emerging retention problems appear. Participants' expectations, staff buy-in, rapport and prior experience shaped the choices. The authors also call for stronger formal evaluation, because many approaches are selected from experience rather than definitive comparative evidence. See the Journal of Clinical Epidemiology study00312-9/fulltext).

Map participant tasks from consent to final follow-up: purpose, time, location or technology, alternatives and the support route. Ask patient and public contributors to test the schedule and materials; tasks that look brief to a team may be onerous for someone managing symptoms, travel or multiple studies.

Define likely risks by population and stage. A participant far from a site may need transport planning; someone with fluctuating symptoms may need a flexible questionnaire window. These are planning examples, not assumptions: ask participants what would make the process workable.

Practical Clinical Trial Retention Strategies

No single intervention prevents dropout. A 2021 Cochrane review found no high-certainty evidence among the comparisons it assessed, and much of the research concerned postal questionnaires rather than site visits. Test approaches in context rather than relying on a universal solution. Review the Cochrane evidence.

1. Set Clear, Realistic Expectations

Explain the number and length of visits, assessments, possible inconvenience, follow-up duration and what may happen if treatment is stopped. Tell participants why each data collection point matters, what is optional, and how to contact the team. Check understanding in a conversation rather than assuming that receipt of a leaflet equals comprehension. Update participants if study procedures change through the approved process.

2. Remove Avoidable Burden

Review questionnaires for duplication and keep only measures that serve a clear purpose. Coordinate study visits where safe and feasible. Consider evening appointments, wider visit windows, local assessments, telephone follow-up or remote options when protocol, safety and data quality allow. Offer paper, phone and digital routes where practical. Accessibility, language needs and reasonable adjustments should be considered during design, not improvised after a participant struggles.

3. Make Contact Predictable And Human

Agree how participants prefer to be contacted and whether they want reminders. Use a consistent schedule and identify a named contact for questions. A reminder should make the next step easy, not shame someone for missing a task. If a participant misses an appointment, a timely, respectful check-in can clarify whether the issue was practical, health-related or a preference to stop. Follow consent choices and approved contact limits.

4. Support Relationships At The Site

Participants often experience the trial through the staff who explain it, answer questions and arrange follow-up. Train the site team on the study, schedule and escalation route. Explain staff handovers. Rapport cannot replace sound procedures, but respectful continuity helps participants raise problems early.

5. Offer Options Without Pressure

Where the protocol allows, offer alternatives such as remote follow-up or a shorter visit. Reimburse reasonable expenses in line with the approved plan and explain the process clearly; avoid framing payments as a reward for staying. Never imply that withdrawing affects ordinary care or that a participant owes the team continued involvement. The Health Research Authority's April 2026 guidance for eligible low-intervention medicine trials says simplified consent must still be informed, freely given, explicit and obtained prospectively; it also says participants' rights, including withdrawal without penalty, must be respected. The simplified arrangements apply only where specified conditions are met, not as a general shortcut. Read the HRA guidance.

6. Treat Feedback As A Retention Signal

Give participants a safe way to report problems and tell them when the team acts on feedback. A check-in after an early visit may reveal unclear instructions, travel difficulty or questionnaire burden. Involve people who reflect the study population, including those facing language, access or digital barriers.

Monitor Retention And Respond To Patterns

Track retention at the level that can guide action: completion of the primary outcome, visit attendance, questionnaire return, treatment discontinuation and withdrawal from further contact. Define each measure in advance, use consistent denominators and distinguish participant-level choices from site-process problems. Look at timing as well as totals: a sudden rise in missed week-eight visits may suggest a specific burden, while gradual loss across sites may point to workload or communication issues.

Record reasons in meaningful, non-judgemental categories. Compare sites and groups carefully: differences may reflect case mix, distance, disease severity or logistics, not staff effort alone. Monitoring should prompt support, not a pressure-inducing league table. Document changes, check implementation and evaluate prospectively where appropriate.

Respect Choice And Learn From Withdrawal

Informed consent is ongoing, not a one-off signature. Participants should know how to raise concerns or change their mind. Explain how treatment discontinuation, assessments, contact preferences and previously collected data will be handled, following the consent materials, protocol, data-protection information and sponsor procedures. Do not promise that data can always be erased or retained.

When someone withdraws, thank them, confirm their choices and record the decision without judgement. If appropriate, invite, but do not require, a reason and feed recurring issues back to the team. Their choice is not a failure; it may reveal a design problem.

Why Retention Starts At Recruitment

Recruitment and retention are closely connected. Finding a person who meets the eligibility criteria is only the first step; that person also needs to understand the study's duration, follow-up schedule and commitments, and to feel supported once they are enrolled. Many retention problems can be traced back to how, where and by whom a participant was first approached.

This is one of the reasons GP-led recruitment works so well. As one of the largest patient recruitment firms in Europe, TrialChoices connects research teams with GP practices that collectively care for 5 million UK patients, with a further 9 million reachable through wider Primary Care Network searches. When a study opportunity is introduced by a patient's own GP, it comes from someone the patient already knows and trusts, using current records that reflect their real health and circumstances. That gives participants a more realistic starting picture, and the GP often remains part of their care throughout the study.

Our researchers page and GP process page explain how the model works, and our patient-selection article covers how suitable participants are identified and referred. For more on why access to live NHS data matters, see our article on why real-time access to UK patient data is a game changer for global clinical trials.

When planning your study, agree early how eligibility will be confirmed, what candidates will learn before deciding, who manages follow-up, how missed visits and withdrawals will be recorded, and how data responsibilities are shared. A clear handoff between recruitment and the site team protects both the participant experience and the quality of your data.

Frequently Asked Questions

How Do You Improve Participant Retention In Clinical Trials?

Plan for retention before recruitment, explain the full time commitment, reduce unnecessary burden, offer practical follow-up options and make contact respectful and predictable. Monitor which tasks participants miss and why, then test changes that fit the protocol and population. No tactic suits every trial.

Why Do Participants Drop Out Of Clinical Trials?

Commonly reported influences include changes in health, competing responsibilities, travel or appointment burden, unclear expectations, and difficulty with repeated data collection. Reasons can change during a study, so teams should ask and record them rather than assume.

What Is The Difference Between Withdrawal And Loss To Follow-Up?

Withdrawal is a participant's choice to stop some or all involvement. Loss to follow-up describes a situation where the team cannot obtain the planned data or contact after appropriate attempts. A missed visit alone is neither necessarily withdrawal nor permanent loss to follow-up.

Can A Participant Stop Treatment But Stay In A Trial?

Sometimes, if the protocol and participant's choice allow it. A person may stop study treatment but agree to safety checks or outcome assessments. Teams should explain the options, respect the participant's decision and follow approved procedures; do not assume continued follow-up is acceptable.

Build Retention Into The Study, Not Around It

Clinical trial participant retention improves when the study is designed around realistic expectations, necessary assessments and respectful relationships. It also improves when participants are recruited through trusted healthcare relationships in the first place. Track missed assessments separately from treatment discontinuation and withdrawal, listen to participants' reasons, and adapt within approved, evidence-aware processes.

Contact TrialChoices

If you want to recruit UK participants through the GPs who already know and care for them, TrialChoices can help. We can talk you through how our GP network identifies suitable patients and how that early relationship supports your study from recruitment onwards.

Call +44 (0)7711 248 610 or email info@trialchoices.org to discuss your study's recruitment and participant needs.


 
 
 

Recent Posts

See All

Comments


bottom of page